Bernard Roubert

1.3k citations

24 papers · 1.0k indexed · h-index 11

Impact in

Genetics top 1%
- Hemoglobinopathies and Related Disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Hematology top 1%
- Iron Metabolism and Disorders
- Acute Myeloid Leukemia Research
- Blood groups and transfusion
- Erythropoietin and Anemia Treatment

Papers in ⓘ

Genetics 21
- Hemoglobinopathies and Related Disorders 21
- Myeloproliferative Neoplasms: Diagnosis and Treatment 8
Hematology 22
- Iron Metabolism and Disorders 13
- Acute Myeloid Leukemia Research 8
- Erythropoietin and Anemia Treatment 4

Co-authors: Dany Habr (22 shared papers)Gabor Domokos (16 shared papers)John B. Porter (12 shared papers)Alì Taher (12 shared papers)Amal El‐Beshlawy (10 shared papers)Mohsen Saleh Elalfy (10 shared papers)Maria Domenica Cappellini (9 shared papers)Chi Kong Li (8 shared papers)
Journals: Blood (9 papers)Leukemia Research (4 papers)Haematologica (4 papers)European Journal Of Haematology (3 papers)Nephrology Dialysis Transplantation (1 paper)
Partner nations: Switzerland Italy United States

In The Last Decade

Bernard Roubert

24 papers receiving 998 citations

Peers

Countries citing papers authored by Bernard Roubert

Since Specialization

Citations

This map shows the geographic impact of Bernard Roubert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Roubert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Roubert more than expected).

Fields of papers citing papers by Bernard Roubert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Roubert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Roubert. The network helps show where Bernard Roubert may publish in the future.

Co-authors

The 25 scholars most cited alongside Bernard Roubert, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bernard Roubert Line = papers co-authored together Bernard Roubert links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias Haematologica ·Maria Domenica Cappellini, John B. Porter, Amal El‐Beshlawy, Chi Kong Li, JANE F. SEYMOUR, Mohsen Saleh Elalfy, Norbert Gattermann, Stéphane Giraudier, J. W. Lee, L L Chan, Kai‐Hsin Lin, Christian Rosé, Alì Taher, SL Thein, Vip Viprakasit, Dany Habr, Gabor Domokos, Bernard Roubert, Antonis Kattamis, (unknown)	2009	233
2	Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia Blood ·Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Amal El‐Beshlawy, Lee Lee Chan, Yeşim Aydınok, Mohsen Saleh Elalfy, Pranee Sutcharitchan, Chi Kong Li, Hishamshah Mohd Ibrahim, Vip Viprakasit, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Alì Taher	2009	158
3	Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study Leukemia Research ·Norbert Gattermann, Carlo Finelli, Matteo Giovanni Della Porta, Pierre Fenaux, Arnold Ganser, Agnès Guerci‐Bresler, Mathias Schmid, Kerry Taylor, (unknown), Sy Ha, Gabor Domokos, Bernard Roubert, Christian Rosé	2010	138
4	Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes Haematologica ·N. Gattermann, Carlo Finelli, Matteo Giovanni Della Porta, Pierre Fenaux, Michael Stadler, A. Guerci-Bresler, Mathias Schmid, K Taylor, (unknown), Dany Habr, Andrea Marcellari, Bernard Roubert, Christian Rose	2012	124
5	Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with -thalassemia major Haematologica ·Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, L L Chan, Amal El‐Beshlawy, Yeşim Aydınok, Hishamshah Mohd Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Alì Taher	2012	107
6	Continued improvement in myocardial T2* over two years of deferasirox therapy in -thalassemia major patients with cardiac iron overload Haematologica ·Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, L L Chan, Amal El‐Beshlawy, Yeşim Aydınok, Hishamshah Mohd Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonios Kattamis, Gordon C. S. Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Alì Taher	2010	61
7	Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial Blood ·Jong Wook Lee, Sung‐Soo Yoon, Zhi Shen, Arnold Ganser, Hui-Chi Hsu, Dany Habr, Gabor Domokos, Bernard Roubert, John B. Porter, (unknown)	2010	56
8	The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale Nephrology Dialysis Transplantation ·Iain C. Macdougall, Andreas Böck, Fernando Carrera, Kai‐Uwe Eckardt, Sandrine Gaillard, David Van Wyck, Bernard Roubert, Timothy Cushway, Simon D. Roger, (unknown)	2013	32
9	Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7‐yr follow‐up from the ESCALATOR study in patients with β‐thalassaemia European Journal Of Haematology ·Alì Taher, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler‐Krahn, Ali El‐Ali, Bernard Roubert, Amal El‐Beshlawy	2011	28
10	Response of iron overload to deferasirox in rare transfusion‐dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias European Journal Of Haematology ·John B. Porter, Kai‐Hsin Lin, Photis Beris, Gian Luca Forni, Alì Taher, Dany Habr, Gabor Domokos, Bernard Roubert, Swee Lay Thein, (unknown)	2011	24
11	Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox International Journal of Hematology ·Vip Viprakasit, Hishamshah Mohd Ibrahim, Sy Ha, Phoebe Joy Ho, Chi Kong Li, Lee Lee Chan, Chang Fang Chiu, Pranee Sutcharitchan, Dany Habr, Gabor Domokos, Bernard Roubert, Hong-Ling Xue, Donald K. Bowden, Kai‐Hsin Lin	2011	10
12	Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β‐thalassaemia: results from the ESCALATOR study European Journal Of Haematology ·Alì Taher, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler‐Krahn, Bernard Roubert, Amal El‐Beshlawy	2011	9
13	Hematologic Responses In Myelodysplastic Syndromes (MDS) Patients Treated with Deferasirox: An EPIC Post-Hoc Analysis Using International Working Group (IWG) 2006 Criteria Blood ·Norbert Gattermann, Carlo Finelli, Matteo Giovanni Della Porta, Pierre Fenaux, Michael Stadler, Agnès Guerci‐Bresler, Mathias Schmid, Kerry Taylor, (unknown), Dany Habr, Andrea Marcellari, Bernard Roubert, Christian Rosé	2010	7
14	Improved Patient Satisfaction, Adherence and Health-Related Quality of Life with Deferasirox (Exjade®) in β-Thalassemia Patients Previously Receiving Other Iron Chelation Therapies. Blood ·John B. Porter, Miranda Athanasiou-Metaxa, Donald K. Bowden, Jacques Troncy, Dany Habr, Gabor Domokos, Bernard Roubert, Diana Rofail, Adam Gater, Jean‐François Baladi, Maria Domenica Cappellini	2009	6
15	Continued Improvement and Normalization of Myocardial T2* In Patients with β-thalassemia Major Treated with Deferasirox (Exjade®) for up to 3 Years Blood ·Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El‐Beshlawy, Yeşim Aydınok, Hishamshah Mohd Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Alì Taher	2010	6
16	Correlation Between Decreased Serum Ferritin and Improved Liver Transaminases During Deferasirox (Exjade®) Treatment in Iron-Overloaded Patients with Myelodysplastic Syndromes. Blood ·Norbert Gattermann, Mathias Schmid, Agnès Guerci‐Bresler, Matteo Giovanni Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Pierre Fenaux	2009	4
17	P140 Reduction in serum ferritin (SF) is associated with improvement in liver transaminase levels during treatment with deferasirox (Exjade®) in ironoverloaded patients with myelodysplastic syndromes (MDS) Leukemia Research ·Norbert Gattermann, Mathias Schmid, A. Guerci-Bresler, Matteo Giovanni Della Porta, K. Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Pierre Fenaux	2009	4
18	Efficacy and Safety of Deferasirox (Exjade®) in β-Thalassemia Patients with Myocardial Siderosis: 2-Year Results From the EPIC Cardiac Sub-Study. Blood ·Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El‐Beshlawy, Yeşim Aydınok, Hishamshah Mohd Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen Saleh Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Alì Taher	2009	4
19	Deferasirox (Exjade®) Is Effective and Well Tolerated in Chelation-Naive and Previously Chelated Patients with Transfusion-Dependent Myelodysplastic Syndromes (MDS). Blood ·Mathias Schmid, Agnès Guerci‐Bresler, Matteo Giovanni Della Porta, Kerry Taylor, Dany Habr, Gabor Domokos, Bernard Roubert, Christian Rosé, Norbert Gattermann	2009	3
20	CONTINUED IMPROVEMENT IN CARDIAC T2WITH DEFERASIROX TREATMENT OVER 2 YEARS: RESULTS FROM THE EXTENSION OF EPIC CARDIAC SUBSTUDY IN BETA-THALASSAEMIA PATIENTS WITH MYOCARDIAL SIDEROSIS UCL Discovery (University College London)* ·Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Ling Ling Chan, Amal El‐Beshlawy, Yeşim Aydınok, Hishamshah Mohd Ibrahim, Chi Kong Li, Viprakasit, Mohsen Saleh Elalfy, Antonios Kattamis, Geoffrey C.S. Smith, Dany Habr, Bernard Roubert, Alì Taher	2010	2

About Bernard Roubert

Bernard Roubert is a scholar working on Genetics, Hematology, Pediatrics, Perinatology and Child Health, Rheumatology and Cardiology and Cardiovascular Medicine, having authored 24 papers that have together received 1.0k indexed citations. Recurring topics across this work include Hemoglobinopathies and Related Disorders (21 papers), Iron Metabolism and Disorders (13 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Acute Myeloid Leukemia Research (8 papers), Erythropoietin and Anemia Treatment (4 papers), Pharmacological Effects and Toxicity Studies (3 papers), Folate and B Vitamins Research (2 papers) and Cardiac Structural Anomalies and Repair (1 paper). The work is most often cited by research in Genetics (914 citations), Hematology (933 citations), Pediatrics, Perinatology and Child Health (164 citations), Nutrition and Dietetics (104 citations) and Orthopedics and Sports Medicine (24 citations). Bernard Roubert has collaborated with scholars based in Switzerland, Italy and United States. Frequent co-authors include Dany Habr, Gabor Domokos, John B. Porter, Alì Taher, Amal El‐Beshlawy, Mohsen Saleh Elalfy, Maria Domenica Cappellini, Chi Kong Li, Vip Viprakasit and Antonis Kattamis. Their work appears in journals such as Blood, Leukemia Research, Haematologica, European Journal Of Haematology and Nephrology Dialysis Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact